PharmaMar has submitted EU marketing authorization application for lurbinectedin in combination with atezolizumabin first-line maintenance therapy for extensive-stage small cell lung cancer

PharmaMar (MSE:PHM) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide. The MAA submission is based on the statistically significant and clinically meaningfulresults from the pivotal Phase 3 IMforte trial. The data of this study will be shared as an oral presentation “Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the Phase 3 IMforte trial” at the  American Society of Clinical Oncology,  ASCO 2025, on June 2nd.

The release as fetched from its publisher. pharmamar.com ↗